Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 Pretax Margin % is % as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100. Among 944 Biotechnology companies, SpyGlass Pharma ranks worse than 105932.1% on this metric.
The historical rank and industry rank for SpyGlass Pharma's Pretax Margin % or its related term are showing as below:
SGP's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.365 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
SpyGlass Pharma Pretax Margin % Related Terms
SpyGlass Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGP vs RIGL, NGNE, OCS: Pretax Margin % Comparison
For the Biotechnology subindustry, SpyGlass Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a Pretax Margin % of % as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SpyGlass Pharma and its competitors. According to the industry distribution chart, SpyGlass Pharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is SpyGlass Pharma's Pretax Margin % too high?
SpyGlass Pharma's current Pretax Margin % is %. Based on the distribution chart, SpyGlass Pharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Pretax Margin % compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #999999 out of 944 companies for Pretax Margin %. This places SpyGlass Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SpyGlass Pharma and its competitors. SpyGlass Pharma's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Pretax Margin % of %. The current Pretax Margin % is %. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Pretax Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
